Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia

NCT01316250 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: Nilotinib

Sponsor

American University of Beirut Medical Center